Britain and America have secured a landmark commercial pact that will ensure no tariffs on British drug shipments entering the American market.
Key Provisions of the Accord
In exchange for the tariff guarantee, the UK has pledged to boost spending on drugs through the National Health Service (NHS). This pledge ensures that duties on these crucial products will be held at zero for a period of the next three years.
This agreement is in response to recent threats to dramatically increase tariffs on patented pharmaceutical products, with figures mentioned up to one hundred percent.
"This agreement with the Britain strengthens the worldwide climate for new treatments and introduces much-needed equity to American-British medicine commerce," a release said.
Trade Impact
Medicines constitute one of the UK's most significant export categories to the America, which is by far the biggest buyer for major companies like GSK and AstraZeneca.
Export figures reveal that in the year to the end of the third quarter, the UK sold pharmaceutical products worth billions to the US. This value accounted for 17.4% of British export trade in that timeframe.
"This deal safeguards employment, increases investment and sets the stage for the UK to emerge as a worldwide center for biotech and pharma," a government official stated.
Key British Pledges
The pact entails several key changes from the United Kingdom:
- Price Threshold Increase: The UK will raise the cost ceiling at which it deems new therapies to be prohibitively costly by 25%.
- Increased NHS Spending: There is a aim to double total health service expenditure on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the coming ten years.
- Rebate Cap: The percentage drug companies must pay back to the NHS to stay within budget will be capped at 15%. Previously, repayments were more than 20%.
Recent Tensions
The deal takes place against a ongoing row between the sector and the British authorities over medicine costs and approval rates.
The disagreement were intensified by assertions that US customers were paying a premium for the same drugs than people in the UK and Europe.
In recent months, several large drug company projects in the UK have been delayed or cancelled, while major expansions have been directed toward projects in the United States.
A senior figure stated that the NHS needed to invest a greater share on medicines, noting that its spending on drugs had shrunk as a proportion of its overall budget over the previous ten-year period.
